Clinical trial · Interventional
Treatment of Menstrual Cycle Alterations in Adolescents
NCT06800170CI-TRIAL-00119949HP-phD_AdolesccompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
the aim of the present study is intended to evaluate how treatment with Myo-Inositol and Dioscorea Villosa can help improve menstrual cycle irregularities in adolescents, both with and without PCOS.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Amenorrhea | — | UNRESOLVED | — |
| Oligomenorrhea | — | UNRESOLVED | — |
| PCOS (Polycystic Ovary Syndrome) | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| myo-Inositol plus DIoscorea Villosa | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Treated Group HP+phD
- interventionNames
- Dietary Supplement: myo-Inositol plus DIoscorea Villosa
- type
- NO_INTERVENTION
- label
- Controls
- description
- Not treated patients
Primary outcomes (1)
- measure
- Menstrual cycle regularity
- timeFrame
- 6 months
- description
- The intervention is targed to adolescent patients suffering from menstrual cycle alterations. Particularly, we aim to asses the regularization of the menstrual cycle in those patients with polimenhorrea and oligo-/ amenorrhea, with irregular menstrual cycle (shorter than 21 days or longer than 35 days). The purpose of the study is to compare the percentage of patients exhibiting a regular menstrual cycle at the end of the treatment period, in the study group vs control.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 14 Years
- Maximum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * adolescent women aged 14-19 years old, with at least 3 years passed after menarche, and oligomenorrhea or amenorrhea Exclusion Criteria: * Primary amenorrhea. * Hyperandrogenism due to other factors (i.e. adrenal hyperplasia or Cushing syndrome). * Hyperprolactinemia or overt hypothyroidism (TSH ≥4). * Other hormonal alterations. * Ongoing hormonal therapies, including OCPs, six months before enrollment. * Ongoing pharmacological therapies. * Ongoing use of myo-Inositol supplement or other source of myo-Inositol, or Dioscorea villosa, six months before enrollment.
References
Publications (0)
Data not yet available
No reference posted for this study.